Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment

Fig. 3

Comparison of cumulative rates of the maintenance of clinical response between A vedolizumab and tofacitinib in UC patients and B vedolizumab and ustekinumab in CD patients. There were no significant differences in the cumulative rates of the maintenance of clinical response between the vedolizumab and tofacitinib groups in UC patients (p = 0.396) or the vedolizumab and ustekinumab groups in CD patients (p = 0.692) as of week 48 of maintenance therapy. UC, ulcerative colitis; CD, Crohn’s disease

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us